NEW YORK, May 19, 2005 (PRIMEZONE) -- Advanced Plant Pharmaceuticals, Inc. (OTCBB:APPI) and its majority owned subsidiary, Mazal Plant Pharmaceuticals Inc., announced today that Mazal received approval from the United States Food and Drug Administration (FDA) on the IND application for MAHDL01, a pharmaceutical drug geared towards improving HDL/ Cholesterol levels.
Dr. Kanovsky, President of Mazal Plant Pharmaceuticals, said, "It is truly gratifying to receive an IND from the FDA on our Investigational new drug MAHDL. We are working on proceeding with the Phase I/II clinical trials for MAHDL. Our team has worked hard to submit a strong INDA and we look forward to continue benefiting from that effort as we progress to the patient recruitment phase."
Mr. David Lieberman, CEO of Advanced Plant Pharmaceuticals (APPI) said, "We are excited by the rapid progress in the development of MAHDL01. As a majority owner of Mazal, the management of APPI are very encouraged with the receipt of the IND for MAHDL01."
About Advanced Plant Pharmaceuticals, Inc.
Advanced Plant Pharmaceuticals, Inc. (APPI) focuses on the research and development of whole plant-based products. APPI has a composition-oriented patent for a proprietary process of utilizing whole plants to manufacture more efficacious all-natural nutritional supplements. For more information, visit the Company's Corporate website: http://www.advancedplantpharm.com
About Mazal Pharmaceuticals, Inc.
Mazal Pharmaceuticals is focused on developing a treatment of hypercholesterolemia / lipidemia. Mazal Plant Pharmaceuticals is an innovator of whole plant pharmaceuticals Drugs focused on the utilization of whole plants in the development of healthier pharmaceutical drugs for the treatment of human diseases. Corporate website: http://www.mazal.cc
Forward-Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.